Biological Voyage of Solid Lipid nanoparticles: A Proficient Carrier in Nanomedicine

Ali, Hasan; Singh, Sandeep Kumar

doi:10.4155/tde-2016-0038

Cited by 23 publications

(10 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…administration, where the drug is already in circulation, and topical application in which the drug is applied to the desired site directly. In the gastrointestinal tract (GIT), the drug passes through a layer of 37 To overcome the problems of poor absorption and low bioavailability of drugs, due to low solubility and/or low permeability, such molecules need to be circulated by employing various nanocarriers. The developed and validated bioanalytical method was fruitfully implemented to evaluate the pharmacokinetic parameters aer oral administration of FSLN and FSP.…”

Section: Pharmacokinetics Studymentioning

confidence: 99%

In vitro–in vivo and pharmacokinetic evaluation of solid lipid nanoparticles of furosemide using Gastroplus™

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Pharmacokinetics Studymentioning

confidence: 99%

In vitro–in vivo and pharmacokinetic evaluation of solid lipid nanoparticles of furosemide using Gastroplus™

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…The matrix of the lipid core has a significant role in regulating the release pattern and protects the loaded drugs from chemical and enzymatic degradation 26,27 . In SLNs, the matrix is a composition of high melting solid lipids, different from the liposome and emulsion, where the vesicles and droplets are made up of low melting phospholipids and liquid oil, respectively 28 . Lipid-based formulations can decrease drug toxicity and improve bioavailability due to its unique physiological and biodegradable properties 27 .…”

mentioning

confidence: 99%

Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis

Parvez

Yadagiri

Gedda

et al. 2020

Sci Rep

View full text Add to dashboard Cite

The development of an effective oral therapeutics is an immediate need for the control and elimination of visceral leishmaniasis (VL). We exemplify the preparation and optimization of 2-hydroxypropyl-β-cyclodextrin (HPCD) modified solid lipid nanoparticles (SLNs) based oral combinational cargo system of Amphotericin B (AmB) and Paromomycin (PM) against murine VL. The emulsion solvent evaporation method was employed to prepare HPCD modified dual drugloaded solid lipid nanoparticles (m-DDSLNs). The optimized formulations have a mean particle size of 141 ± 3.2 nm, a polydispersity index of 0.248 ± 0.11 and entrapment efficiency for AmB and PM was found to be 96% and 90% respectively. The morphology of m-DDSLNs was confirmed by scanning electron microscopy and transmission electron microscopy. The developed formulations revealed a sustained drug release profile upto 57% (AmB) and 21.5% (PM) within 72 h and were stable at both 4 °C and 25 °C during short term stability studies performed for 2 months. Confocal laser scanning microscopy confirmed complete cellular internalization of SLNs within 24 h of incubation. In vitro cytotoxicity study against J774A.1 macrophage cells confirmed the safety and biocompatibility of the developed formulations. Further, m-DDSLNs did not induce any hepatic/renal toxicities in Swiss albino mice. The in vitro simulated study was performed to check the stability in simulated gastric fluids and simulated intestinal fluids and the release was found almost negligible. The in vitro anti-leishmanial activity of m-DDSLNs (1 µg/ml) has shown a maximum percentage of inhibition (96.22%) on intracellular amastigote growth of L. donovani. m-DDSLNs (20 mg/kg × 5 days, p.o.) has significantly (P < 0.01) reduced the liver parasite burden as compared to miltefosine (3 mg/kg × 5 days, p.o.) in L. donovani-infected BALB/c mice. This work suggests that the superiority of as-prepared m-DDSLNs as a promising approach towards the oral delivery of anti-leishmanial drugs. Visceral leishmaniasis (VL), also known as Kala-Azar is the most severe form of leishmaniasis, a neglected tropical disease caused by the protozoan parasite Leishmania donovani, The disease is transmitted to human host by the bite of an infected female haemo-flagellate sand fly 1. According to WHO, 0.5-0.9 million new VL cases are reported every year, > 95% of which occur in ten countries Bangladesh,

show abstract

“…They are free from chronic and acute toxicity, are biocompatible, and could provide a controlled and targeted release to a specific site. The lipid matrix plays an important role in controlling drug release and protecting the drug from degradable enzymes [ 109 , 110 ].…”

Section: Novel Ocular Therapeutic Systemsmentioning

confidence: 99%

Drug Delivery Challenges and Current Progress in Nanocarrier-Based Ocular Therapeutic System

Akhter

Ahmad

Alshahrani

et al. 2022

Gels

View full text Add to dashboard Cite

Drug instillation via a topical route is preferred since it is desirable and convenient due to the noninvasive and easy drug access to different segments of the eye for the treatment of ocular ailments. The low dose, rapid onset of action, low or no toxicity to the local tissues, and constrained systemic outreach are more prevalent in this route. The majority of ophthalmic preparations in the market are available as conventional eye drops, which rendered <5% of a drug instilled in the eye. The poor drug availability in ocular tissue may be attributed to the physiological barriers associated with the cornea, conjunctiva, lachrymal drainage, tear turnover, blood–retinal barrier, enzymatic drug degradation, and reflex action, thus impeding deeper drug penetration in the ocular cavity, including the posterior segment. The static barriers in the eye are composed of the sclera, cornea, retina, and blood–retinal barrier, whereas the dynamic barriers, referred to as the conjunctival and choroidal blood flow, tear dilution, and lymphatic clearance, critically impact the bioavailability of drugs. To circumvent such barriers, the rational design of the ocular therapeutic system indeed required enriching the drug holding time and the deeper permeation of the drug, which overall improve the bioavailability of the drug in the ocular tissue. This review provides a brief insight into the structural components of the eye as well as the therapeutic challenges and current developments in the arena of the ocular therapeutic system, based on novel drug delivery systems such as nanomicelles, nanoparticles (NPs), nanosuspensions, liposomes, in situ gel, dendrimers, contact lenses, implants, and microneedles. These nanotechnology platforms generously evolved to overwhelm the troubles associated with the physiological barriers in the ocular route. The controlled-drug-formulation-based strategic approach has considerable potential to enrich drug concentration in a specific area of the eye.

show abstract

Biological Voyage of Solid Lipid nanoparticles: A Proficient Carrier in Nanomedicine

Cited by 23 publications

References 149 publications

In vitro–in vivo and pharmacokinetic evaluation of solid lipid nanoparticles of furosemide using Gastroplus™

In vitro–in vivo and pharmacokinetic evaluation of solid lipid nanoparticles of furosemide using Gastroplus™

Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis

Drug Delivery Challenges and Current Progress in Nanocarrier-Based Ocular Therapeutic System

Contact Info

Product

Resources

About